Antihypertensive Effect of Oxprenolol and Chlorthalidone in Fixed Combination, Given Once Daily

1979 ◽  
Vol 7 (6) ◽  
pp. 519-523 ◽  
Author(s):  
R Buoninconti ◽  
M Motolese ◽  
M Rubegni
Keyword(s):  
Clinical Response ◽  
Patient Compliance ◽  
Moderate Hypertension ◽  
Antihypertensive Effect ◽  
Fixed Combination ◽  
Once Daily ◽  
Patient Study ◽  
Treatment Regimes ◽  
Significant Difference ◽  
Single Blind

In a multicentre, single-blind, within-patient study, the effectiveness and tolerability of the fixed combination oxprenolol 80 mg + chlorthalidone 10 mg per tablet given once daily, compared to the well established b.i.d. schedule, has been investigated in forty out-patients with mild to moderate hypertension. After a two-weeks placebo wash-out, twenty patients were given 1 tablet b.i.d. of the fixed combination for 4 weeks and thereafter 2 tablets once-daily for a further 4 weeks; the remaining twenty patients were given the fixed combination in the reverse order. There was no significant difference in clinical response between the two treatment regimes, which were equally effective and well tolerated. However, patient compliance might be considerably improved with the once-daily dosage schedule of the fixed combination.

Comparison of a Once Daily Long-Acting Formulation of Propranolol with Conventional Propranolol Given Twice Daily in Patients with Mild to Moderate Hypertension

1979 ◽  
Vol 7 (3) ◽  
pp. 221-223 ◽  
Author(s):  
A P Douglas-Jones
Keyword(s):  
Clinical Response ◽  
Patient Compliance ◽  
Moderate Hypertension ◽  
Dosage Schedule ◽  
Once Daily ◽  
Significant Difference ◽  
Long Acting

The effect of conventional propranolol tablets given twice daily has been compared with an equivalent dosage of a long-acting formulation of propranolol ('Inderal’ LA)p given once daily in twenty-nine patients with mild to moderate hypertension. The study lasted 10 weeks. There was no significant difference in clinical response to the two treatments which were equally effective and well tolerated. A once daily dosage schedule should greatly aid patient compliance.

Experiences with Metoprolol Durules®, A Slow-Release Formulation in Hypertension

1980 ◽  
Vol 8 (1) ◽  
pp. 44-49 ◽  
Author(s):  
Jaakko Tuomilehto ◽  
Aulikki Nissinen
Keyword(s):  
Blood Pressure ◽  
Diastolic Blood Pressure ◽  
Moderate Hypertension ◽  
Antihypertensive Effect ◽  
Slow Release ◽  
Final Dose ◽  
Release Formulation ◽  
Once Daily ◽  
Slow Release Formulation ◽  
The Mean

The antihypertensive effect and the tolerability of metoprolol Durules® have been studied in fifty-five patients with mild to moderate hypertension. The patients' diastolic blood pressure was ≥95 mm Hg in order to qualify for entry. Thirty-seven out of fifty-three patients completing the study (70%) were treated with metoprolol Durules® monotherapy throughout the study. The mean blood pressure was reduced from 153/101 to 138/92 mm Hg after metoprolol Durules® compared to placebo (p < 0.001). Twenty-seven patients received one Durules® daily and ten patients received two Durules® daily as the final dose. Of the sixteen patients not responding on metoprolol Durules®, six patients achieved satisfactory control, i.e. a diastolic blood pressure below 95 mm Hg, when given 200 mg metoprolol + 25 mg hydrochlorothiazide (HCT). The results indicate that most patients with, mild or moderate hypertension can be controlled with metoprolol Durules® monotherapy given once daily. The addition of HCT gives a significant benefit in moderate hypertension, where metoprolol monotherapy is not sufficient.

A Clinical Trial of ICI 58,834 – A Potential Anti-Depressant

1973 ◽  
Vol 1 (7) ◽  
pp. 624-626 ◽  
Author(s):  
Malcolm Peet
Keyword(s):  
Clinical Trial ◽  
Clinical Response ◽  
Rating Scale ◽  
Controlled Trial ◽  
Antidepressant Activity ◽  
Depressive Illness ◽  
Blood Levels ◽  
Significant Difference ◽  
Single Blind ◽  
Hamilton Rating Scale

Twenty-four in-patients with depressive illness were treated with either ICI 58,834 or imipramine for twenty-one days in a single-blind controlled trial. No statistically significant difference in response was found between the two groups, as assessed by the Hamilton Rating Scale and the Beck Depression Inventory. Blood levels of ICI 58,834 at one hour were not correlated with clinical response. Nausea and vomiting occurred in three patients taking ICI 58,834. It is concluded that further investigation of the apparent antidepressant activity of this new drug is indicated.

Atenolol vs. Amiloride-Hydrochlorothiazide in the Treatment of Mild to Moderate Hypertension: A Double-Blind, Crossover, Placebo-Controlled Study

1987 ◽  
Vol 21 (1) ◽  
pp. 43-46 ◽  
Author(s):  
Michael Lischner ◽  
Ruth Lang ◽  
Itzhak Jutrin ◽  
Mordchai Ravid
Keyword(s):  
Moderate Hypertension ◽  
Antihypertensive Effect ◽  
Blocking Agent ◽  
Associate Professor ◽  
Senior Resident ◽  
Controlled Study ◽  
Double Blind ◽  
Once Daily ◽  
Tel Aviv ◽  
School Of Medicine

The antihypertensive effect of atenolol 100 mg was compared to that of amiloride HCl 5 mg + hydrochlorothiazide 50 mg (AHCZ) in a double-blind, crossover, placebo-controlled study of 128 patients. Both drugs were given once daily. Atenolol produced a significant decline in lying, standing, and postexercise blood pressure and pulse rate values. The corresponding values on AHCZ were not significantly different from placebo. Both the beta-blocking agent and the thiazide diuretic with amiloride were relatively well tolerated. More than half of all adverse effects were nonspecific and also observed in patients on placebo. In the population studied, atenolol proved to be a superior antihypertensive agent to AHCZ. MICHAEL LISCHNER, M.D., is Senior Resident, Instructor in Medicine; RUTH LANG, M.D., is Physician, Lecturer in Medicine; ITZHAK JUTRIN, M.D., is Senior Physician; and MORDCHAI RAVID, M.D., is Head, Department of Medicine, Associate Professor of Medicine, Meir Hospital, Kfar Saba, and Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel.

scholarly journals Prospective, randomized double blind comparative study of safety and efficacy of carvedilol versus atenolol in patients of mild to moderate hypertension

2017 ◽  
Vol 6 (7) ◽  
pp. 1678
Author(s):  
Swathi Ratnam R. ◽  
Usha Kiran P. ◽  
S. V. R. Rajasekhar ◽  
M. Prasad Naidu
Keyword(s):  
Blood Pressure ◽  
Moderate Hypertension ◽  
Treatment Phase ◽  
Study Groups ◽  
Response To Therapy ◽  
Double Blind ◽  
Once Daily ◽  
Significant Difference ◽  
The Mean ◽  
Atenolol Group

Background: Carvedilol is a new cardiovascular compound with the combined pharmacologic properties of nonselective ß-blockade and vasodilation. The Aim of the study was to compare the safety and antihypertensive efficacy of 25mg Carvedilol once daily with 50mg atenolol once daily in patients with mild to moderate essential hypertension.Methods: This was a single center study conducted in Rangaraya Medical College, Kakinada. 80 eligible patients with mild to moderate hypertension were randomized to receive 25mg Carvedilol once daily (40 patients) or 50mg atenolol (40 patients) in a double-blind 12-week treatment phase. At each visit 0, 4, 8 and 12 weeks of treatment, sitting Blood Pressure (BP) and heart rate were measured. The effect on BP reduction within the group is compared by paired “t”test and the effect on reduction of BP between two study groups compared by unpaired “t”test.Results: After 12 weeks of treatment, the mean reduction of SBP (Systolic Blood Pressure) with carvedilol is 22.33±8.31mmHg with no Significant difference (p >0.05) compared to atenolol group mean reduction in SBP of 21.37±10mm Hg. The mean reduction in DBP (Diastolic Blood Pressure) after completion of the study in carvedilol group is 6.75±4.82mm Hg with no Significant difference (p >0.05) compared to atenolol group mean reduction in DBP of 8.55±5.25mm Hg. No significant difference seen in the efficacy parameters of both the drugs. The incidence of adverse effects such as bradycardia, headache, nausea, vomiting, hypotension and rash is less with carvedilol.Conclusions: In patients with mild to moderate hypertension, there was no statistically significant difference between efficacy of carvedilol or atenolol with regard to the degree of reduction in BP or the percentage of patients achieving a response to therapy but carvedilol showed a better safety profile when compared to atenolol.

Ramosetron for the Prevention of Cisplatin-Induced Acute Emesis: A Prospective Randomized Comparison with Granisetron

2002 ◽  
Vol 30 (3) ◽  
pp. 220-229 ◽  
Author(s):  
YK Kang ◽  
YH Park ◽  
BY Ryoo ◽  
YJ Bang ◽  
KS Cho ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Patient Compliance ◽  
Adult Patients ◽  
Nausea And Vomiting ◽  
Blind Study ◽  
Acute Emesis ◽  
Significant Difference ◽  
Equivalent Efficacy ◽  
To Receive ◽  
Single Blind

Control of nausea and vomiting is very important in determining patient compliance with cisplatin chemotherapy. A multicentre, randomized, single-blind study was conducted to compare the tolerability and efficacy of ramosetron with those of granisetron over 24 h following cisplatin administration to cancer patients. In eight study centres, a total of 194 adult patients were randomly assigned to receive either intravenous ramosetron 0.3 mg or intravenous granisetron 3.0 mg. The anti-emetic effect of ramosetron determined from the no-vomiting rate lasted longer, but there was no significant difference in the number of acute vomiting episodes or the severity of nausea between the two groups. In the tolerability evaluation, there were no statistically significant differences between the two groups, except for a higher incidence of dull headache in the granisetron group. Ramosetron and granisetron appear to have equivalent efficacy and tolerability profiles, but the effects of ramosetron on the prevention of acute vomiting in patients undergoing cisplatin chemotherapy were longer lasting.

A Study of Once Daily Tenormin (Atenolol) in Hypertension: Some Implications in Patient Compliance

1976 ◽  
Vol 4 (5) ◽  
pp. 347-351 ◽  
Author(s):  
A M Harris ◽  
K V Woollard ◽  
J A Tweed
Keyword(s):  
Blood Pressure ◽  
Drug Therapy ◽  
Clinical Study ◽  
Side Effects ◽  
Patient Compliance ◽  
Pressure Control ◽  
Once Daily ◽  
Hypertensive Patients ◽  
Significant Difference ◽  
Pre Treatment

A clinical study is described in which hypertensive patients on no drug therapy were given atenolol in increasing doses from 50 mg twice daily to 200 mg twice daily until the diastolic blood pressure was 90 mm Hg or below. At this stage the drug was withdrawn until blood pressure readings had risen to pre-treatment levels. The same dose of atenolol was then re-introduced but now given once-a-day (in the morning) and was continued for four weeks. Of the eleven patients entering the study, one withdrew as his blood pressure was not controlled on a dose of 200 mg of atenolol twice daily, and another because on withdrawal of atenolol his blood pressure did not rise to pre-treatment levels. The remaining nine patients completed the study. There was a statistically significant fall in blood pressure on both atenolol regimes and there was no significant difference between the blood pressure control achieved on twice-a-day and once-a-day administration. Only one patient developed side-effects; this being an asthmatic who developed mild dyspnoea on atenolol which did not necessitate withdrawal of the drug. It is concluded that once-a-day administration of a given dose of atenolol is therapeutically equivalent to twice-a-day administration. The implications of this in terms of better patient compliance, and thus better prognosis, are discussed.

The possible regulatory mechanisms of aqueous, ethyl acetate and nhexane fractions of the Ribes khorassanicum extract on acute hypertension in rats

2020 ◽  
Vol 20 ◽  
Author(s):  
Reza Mohebbati ◽  
Yasamin Kamkar-De ◽  
Mohammad Naser Shafei
Keyword(s):  
Ethyl Acetate ◽  
Antihypertensive Effect ◽  
Cardiovascular Responses ◽  
Regulatory Mechanisms ◽  
Hypertensive Rats ◽  
Control Groups ◽  
Acute Hypertension ◽  
The North ◽  
Significant Difference ◽  
And Control

Objective: Our previous studies showed the antihypertensive effect of Ribes khorassanicum (R. khorassanicum), a medicinal herb growing in the North Khorasan Province of Iran. For further evaluation, the present study investigated the effect of n-hexane (HX), ethyl acetate (EA), and aqueous (AQ) fractions of hydroalcoholic R. khorassanicum extract on cardiovascular responses in angiotensin II (AngII) and NG-nitro-L-arginine methyl ester (L-NAME) hypertensive rats. Methods: Wistar rats were randomly divided into 11 groups (n=5): 1) control, 2) AngII (50 ng/kg, i.v), 3) AngII + losartan (10 mg/kg, i.p), 4) L-NAME (10 mg/kg, i.v), 5) L-NAME+ sodium nitroprusside (SNP) (50 mg/kg, i.p), 6,7,8) one dose of each fraction of R. khorassanicum (AQ/EA/HX (50 mg/kg, i.p)) +AngII, and 9,10,11) one dose of each fraction of R. khorassanicum (AQ/EA/HX (50 mg/kg, i.p)) + L-NAME. Treated rats received three fractions 30 min before the injection of L-NAME and AngII in separate groups. The cardiovascular parameters were recorded by the Power Lab instrument via an angiocath inserted into the femoral artery. The peak changes (∆) of mean arterial pressure (MAP), systolic blood pressure (SBP), and heart rate (HR) in treated groups were compared with those of the hypertensive and control groups. Result: AngII and L-NAME significantly increased ∆MAP and ∆SBP and attenuated by pretreatment of LOS and SNP, respectively. Pretreatment with polar (AQ) and semipolar (EA) fractions of R. khorassanicum reduced the peak changes of MAP and SBP in both AngII and L-NAME-treated groups. Only the fraction of the herb attenuated the HR increased in the L-NAME group. The HR in other groups did not demonstrate any significant difference. Conclusion: All fractions of R. khorassanicum have an antihypertensive effect. However, the effect of polar fractions is more salient. It is also conceivable that the antihypertensive effect of fractions is mostly mediated by the inhibition of AngII.

Sign in / Sign up

Export Citation Format

Share Document